The BHP Clinical Trials Unit (CTU) has conducted multiple international clinical trials, under the AID Clinical Trials Group (ACTG) and and other related networks, which are high impact and aimed to improve the treatment of HIV and its co-infections, including TB, viral hepatitis and other co-morbidities and seeking to advance approaches to cure HIV. These BHP studies have looked into treatment of opportunistic infections in HIV (A5265), HIV 2nd line treatment strategies (A5234), HIV Pharmacokinetics (A5316), TB diagnostics (A5253), TB prevention (A5279), TB Pharmacokinetic studies (A5338, A5375, A5372), multidrug resistant TB (MDR-TB) prevention (PHOENIx). Currently accruing, the PHOENIx study is incorporating a novel TB drug (Delamanid) to better protect close household contacts of MDR-TB patients while adherence is monitored via an electronic pill box. To highlight one result; the A5279 study showed that only one month of an Isoniazid and Rifapentine combination for TB prevention was comparable to the standard 6-9 months of Isoniazid Preventive Therapy (IPT). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563914/pdf/nihms-1529630.pdf. For the near future, BHP plans to embark on Hepatitis B virus trials which are largely still in development.